OncologyEducation· @OncEd · X·· 16 hours agoScore70
Body
FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs. investigator’s choice in HR+/HER2− mBC after a CDK4/6 inhibitor (median 9.4 vs. 6.6 mo; HR 0.60). Antonio Giordano, MD, PhD @antgiorda, explains Watch now: https://bit.ly/4zPpSD5
13 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: OncologyEducation · x.com